• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Tandem Diabetes Care Inc.

    11/14/24 4:15:44 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care
    Get the next $TNDM alert in real time by email
    SC 13G/A 1 p24-3294sc13ga.htm

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     

    SCHEDULE 13G/A

    Amendment No. 1

     
    Under the Securities Exchange Act of 1934
     
     
    Tandem Diabetes Care, Inc.
    (Name of Issuer)
     
    Common Stock, par value $0.001 per share
    (Title of Class of Securities)
     
    875372203
    (CUSIP Number)
     
    September 30, 2024
    (Date of event which requires filing of this statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:
     

    x Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 7 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 87537220313G/APage 2 of 7 Pages

     

    1

    NAME OF REPORTING PERSON

    Eminence Capital, LP

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ☒

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    0

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0%

    12

    TYPE OF REPORTING PERSON

    IA

             

     

     

     

    CUSIP No. 87537220313G/APage 3 of 7 Pages

     

    1

    NAME OF REPORTING PERSON

    Ricky C. Sandler

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ☒

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    0

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0%

    12

    TYPE OF REPORTING PERSON

    IN

             

     

     

    CUSIP No. 87537220313G/APage 4 of 7 Pages

     

    Item 1(a). Name of Issuer
       
      The name of the issuer is Tandem Diabetes Care, Inc. (the "Company").  

     

    Item 1(b). Address of Issuer's Principal Executive Offices
       
      The Company's principal executive offices are located at 12400 High Bluff Drive, San Diego, California 92130.
       

    Item 2. Name of Person Filing:
       
     

    This statement is filed by Eminence Capital, LP, a Delaware limited partnership (“Eminence Capital”) and Ricky C. Sandler, a U.S. Citizen (“Mr. Sandler,” and together with Eminence Capital, the “Reporting Persons”).

       
     

    Eminence Capital serves as the management company or investment adviser to, and may be deemed to have shared voting and dispositive power over the shares of Common Stock held by, various investment funds (the “Eminence Funds”) and separately managed accounts (the “Eminence SMAs,” and together with the Eminence Funds, the “Eminence Funds and SMAs”) under its management and control. The general partner of Eminence Capital is Eminence Capital GP, LLC, the sole managing member of which is Mr. Sandler.

       
     

    Mr. Sandler is the Chief Executive Officer of Eminence Capital and may be deemed to have shared voting and dispositive power with respect to the shares of Common Stock held by the Eminence Funds and SMAs.

       
      The filing of this statement should not be construed as an admission that any of the Reporting Persons is, for the purposes of Section 13G of the Act, the beneficial owner of the shares of Common Stock reported herein.

     

    Item 2(b). Address of Principal Business Office or, if None, Residence:
       
      The address of the principal business and principal office of Eminence Capital is 399 Park Avenue, 25th Floor, New York, NY  10022.  The business address of Mr. Sandler is 399 Park Avenue, 25th Floor, New York, NY  10022.

     

    Item 2(c). Citizenship
       
     

    Eminence Capital is a limited partnership organized under the laws of the State of Delaware. Mr. Sandler is a United States citizen.

     

    Item 2(d). Title of Class of Securities
       
      Common Stock, $0.001 par value (the "Common Stock").

     

    Item 2(e). CUSIP Number
       
      875372203

     

    CUSIP No. 87537220313G/APage 5 of 7 Pages

     

    Item 3. If this statement is filed pursuant to Rules 13d-1(b) or 13d-2(b) or (c), check whether the person filing is a:

     

      (a) ¨ Broker or dealer registered under Section 15 of the Act;
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act;
      (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act;
      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940;
      (e) x An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
      (f) ¨ An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

      (g) x A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
      (h) ¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;
      (i) ¨ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;
      (j) ¨ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

      If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J),  
      please specify the type of institution:    
             

    Item 4 Ownership
       
     

    See rows (9) and (11) of the cover pages to this Schedule 13G/A for the aggregate number of shares of Common Stock and the percentage of the shares of Common Stock beneficially owned by the Reporting Persons.

       
     

    See rows (5) through (8) of the cover pages to this Schedule 13G/A for the number of shares of Common Stock as to which each Reporting Person has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition.

     

    CUSIP No. 87537220313G/APage 6 of 7 Pages

     

    Item 5. Ownership of Five Percent or Less of a Class
       
      This statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than 5 percent of the class of securities.

       
    Item 6. Ownership of More than Five Percent on Behalf of Another Person
       
      Not applicable. 

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
       
      Not Applicable.

     

    Item 8. Identification and Classification of Members of the Group.
       
      Not Applicable.

     

    Item 9. Notice of Dissolution of Group.
       
      Not Applicable.

     

    Item 10. Certification

     

      Each of the Reporting Persons hereby makes the following certification:
       
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

    CUSIP No. 87537220313G/APage 7 of 7 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    DATE: November 14, 2024

     

      /s/ Ricky C. Sandler
      Ricky C. Sandler, individually, and as Chief Executive Officer of Eminence Capital, LP

     

     

    Get the next $TNDM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TNDM

    DatePrice TargetRatingAnalyst
    6/16/2025$24.00Hold
    Truist
    4/10/2025$20.00Neutral
    Mizuho
    3/5/2025$45.00 → $22.00Overweight → Equal-Weight
    Morgan Stanley
    3/4/2025$35.00 → $24.00Buy → Neutral
    Citigroup
    3/3/2025$38.00 → $22.00Overweight → Equal Weight
    Wells Fargo
    2/28/2025$35.00 → $25.00Outperform → Mkt Perform
    Bernstein
    12/2/2024$45.00Equal-Weight → Overweight
    Morgan Stanley
    11/6/2024$42.00Outperform
    Bernstein
    More analyst ratings

    $TNDM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Technology Officer Carpenter Rick converted options into 406 shares and covered exercise/tax liability with 207 shares, increasing direct ownership by 0.95% to 21,219 units (SEC Form 4)

      4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)

      6/18/25 4:08:32 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • EVP & CHIEF COMMERCIAL OFFICER Novara Mark David converted options into 7,414 shares and covered exercise/tax liability with 3,846 shares, increasing direct ownership by 14% to 28,763 units (SEC Form 4)

      4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)

      6/18/25 4:08:21 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • Director Cha Myoungil converted options into 1,749 shares, increasing direct ownership by 15% to 13,699 units (SEC Form 4)

      4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)

      6/18/25 4:08:10 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care

    $TNDM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP & Chief Operating Officer Kyrillos Jean-Claude bought $190,966 worth of shares (10,538 units at $18.12) (SEC Form 4)

      4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)

      3/11/25 6:06:01 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • EVP & CHIEF COMMERCIAL OFFICER Novara Mark David bought $12,364 worth of shares (532 units at $23.24) (SEC Form 4)

      4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)

      11/19/24 5:23:14 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • Allen Dick bought $94,778 worth of shares (5,000 units at $18.96), increasing direct ownership by 33% to 19,962 units (SEC Form 4)

      4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)

      11/29/23 4:10:39 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care

    $TNDM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Truist initiated coverage on Tandem Diabetes Care with a new price target

      Truist initiated coverage of Tandem Diabetes Care with a rating of Hold and set a new price target of $24.00

      6/16/25 7:53:54 AM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • Mizuho initiated coverage on Tandem Diabetes Care with a new price target

      Mizuho initiated coverage of Tandem Diabetes Care with a rating of Neutral and set a new price target of $20.00

      4/10/25 12:43:51 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • Tandem Diabetes Care downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Tandem Diabetes Care from Overweight to Equal-Weight and set a new price target of $22.00 from $45.00 previously

      3/5/25 7:47:44 AM ET
      $TNDM
      Medical/Dental Instruments
      Health Care

    $TNDM
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • February 28, 2025 - FDA Roundup: February 28, 2025

      For Immediate Release: February 28, 2025 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:On Thursday, the FDA approved Odactra to include use in individuals 5 through 11 years of age to treat house dust mite induced nasal inflammation (allergic rhinitis), with or without eye inflammation (conjunctivitis). Odactra is an allergen extract immunotherapy

      2/28/25 5:00:47 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • November 7, 2023 - FDA Roundup: November 7, 2023

      For Immediate Release: November 07, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  On Monday, the FDA issued a Safety Communication warning consumers, health care providers, and health care facilities not to use recalled saline (0.9% sodium chloride) and sterile water medical products manufactured by Nurse Assist, LLC. On November 6, Nurse

      11/7/23 3:38:18 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care